Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DNA immunisation with minimalistic expression constructs.

S Moreno1, L López-Fuertes, A J Vila-Coro

  • 1Mologen Molecular Medicines S L, C/Antonio de Cabezón 83, Piso 2, 28034 Fuencarral, Madrid, Spain.

Vaccine
|April 8, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon.

Mucosal immunology·2017
Same author

Immune response of healthy horses to DNA constructs formulated with a cationic lipid transfection reagent.

BMC veterinary research·2015
Same author

Influences of age and sex on leukocytes of healthy horses and their ex vivo cytokine release.

Veterinary immunology and immunopathology·2015
Same author

Assessment of parental genomic proportions in crossbred chickens by DNA fingerprints.

Journal of animal breeding and genetics = Zeitschrift fur Tierzuchtung und Zuchtungsbiologie·2011
Same author

[Chronic inflammatory intestinal diseases. Pathophysiology and therapy].

Der Internist·2009

New DNA vaccine technology using minimalistic, immunogenically defined gene expression (MIDGE) vectors overcomes limitations of traditional plasmid DNA vaccines. These novel vectors show efficacy in generating antigen-specific immune responses in mice.

Area of Science:

  • Molecular Biology
  • Immunology
  • Vaccinology

Background:

  • Plasmid-based DNA vaccines face challenges with low efficacy in large animals and the inclusion of antibiotic resistance markers.
  • Conventional plasmid vectors contain non-essential sequences that may pose risks.

Purpose of the Study:

  • To introduce and evaluate minimalistic, immunogenically defined gene expression (MIDGE) vectors as an alternative for DNA vaccination.
  • To assess the potential of MIDGE vectors for generating and manipulating antigen-specific immune responses.

Main Methods:

  • Development of linear, covalently-closed MIDGE vectors lacking plasmid backbone sequences.
  • Chemical modification of MIDGE vectors for targeted delivery to specific cells or cellular compartments.
  • Immunization of mice with both simple and end-modified MIDGE vectors.

Related Experiment Videos

Main Results:

  • MIDGE vectors successfully expressed genes and were shown to be effective in generating immune responses.
  • End-modified MIDGE vectors demonstrated potential for targeted DNA delivery.
  • Antigen-specific immune responses were successfully generated and manipulated in mice.

Conclusions:

  • MIDGE vectors represent a promising, safer, and potentially more effective platform for DNA vaccination compared to conventional plasmids.
  • The modular nature of MIDGE vectors allows for targeted delivery, enhancing their versatility.
  • These findings support the commercial viability of DNA vaccines by addressing key limitations.